The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
L. M. McGregor
No relevant relationships to disclose
S. L. Spunt
Research Funding - Sanofi
D. Ward
No relevant relationships to disclose
J. Wu
No relevant relationships to disclose
C. Billups
No relevant relationships to disclose
S. P. Ivy
No relevant relationships to disclose
V. M. Santana
No relevant relationships to disclose
M. Fouladi
No relevant relationships to disclose
W. L. Furman
No relevant relationships to disclose